Cargando…

Peripheral Blood Biomarkers for Early Diagnosis, Severity, and Prognosis of Checkpoint Inhibitor-Related Pneumonitis in Patients With Lung Cancer

BACKGROUND: Checkpoint inhibitor-related pneumonitis (CIP) is a potentially fatal immune-related adverse event that occurs during treatment with immune checkpoint inhibitors (ICIs). However, the roles played by peripheral blood parameters in CIP development remain unclear. Here, we aimed to identify...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lin, Xinqing, Deng, Haiyi, Yang, Yilin, Wu, Jianhui, Qiu, Guihuan, Li, Suyang, Xie, Xiaohong, Liu, Ming, Xie, Zhanhong, Qin, Yinyin, Song, Yong, Zhou, Chengzhi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8313853/ https://www.ncbi.nlm.nih.gov/pubmed/34327140 http://dx.doi.org/10.3389/fonc.2021.698832

Ejemplares similares

Immune Checkpoint Inhibitors Plus Single-Agent Chemotherapy for Advanced Non-Small-Cell Lung Cancer After Resistance to EGFR-TKI
por: Deng, Haiyi, et al.
Publicado: (2021)

Comprehensive Analysis of the Immune Microenvironment in Checkpoint Inhibitor Pneumonitis
por: Lin, Xinqing, et al.
Publicado: (2022)

Safety and efficacy of immunotherapy rechallenge following checkpoint inhibitor-related pneumonitis in advanced lung cancer patients: a retrospective multi-center cohort study
por: Lin, Xinqing, et al.
Publicado: (2022)

Successful management of Epstein‑Barr virus‑associated severe checkpoint inhibitor‑related pneumonitis: A case report
por: Deng, Jiaxi, et al.
Publicado: (2023)

Clinical types of checkpoint inhibitor-related pneumonitis in lung cancer patients: a multicenter experience
por: Lin, Xinqing, et al.
Publicado: (2021)

The Treatment Status of Patients in NSCLC With RET Fusion Under the Prelude of Selective RET-TKI Application in China: A Multicenter Retrospective Research
por: Meng, Yan, et al.
Publicado: (2022)

Proposed clinical phases for the improvement of personalized treatment of checkpoint inhibitor–related pneumonitis
por: Zhou, Chengzhi, et al.
Publicado: (2022)

Prognostic Biomarker TP53 Mutations for Immune Checkpoint Blockade Therapy and Its Association With Tumor Microenvironment of Lung Adenocarcinoma
por: Lin, Xinqing, et al.
Publicado: (2020)

Identification and validation of a ferroptosis-related prognostic risk-scoring model and key genes in small cell lung cancer
por: Li, Suyang, et al.
Publicado: (2022)

Evaluation of Cell Surface Vimentin Positive Circulating Tumor Cells as a Diagnostic Biomarker for Lung Cancer
por: Xie, Xiaohong, et al.
Publicado: (2021)

Case Report: A Rare Case of Metachronous Multiple Primary Lung Cancers in a Patient With Successful Management by Switching From Anti-PD-1 Therapy to Anti-PD-L1 Therapy
por: Lin, Xinqing, et al.
Publicado: (2021)

Immune thrombocytopenia in a small cell lung cancer patient treated with atezolizumab: a case report
por: Qiu, Guihuan, et al.
Publicado: (2022)

A retrospective real‐world experience of immunotherapy in patients with extensive stage small‐cell lung cancer
por: Qiu, Guihuan, et al.
Publicado: (2023)

Case Report: Fatal Multiorgan Failure and Heterochronous Pneumonitis Following Pembrolizumab Treatment in a Patient With Large-Cell Neuroendocrine Carcinoma of Lung
por: Xie, Xiaohong, et al.
Publicado: (2021)

Multi-organ Immune-Related Adverse Event Is a Risk Factor of Immune Checkpoint Inhibitor-Associated Myocarditis in Cancer Patients: A Multi-center Study
por: Xie, Xiaohong, et al.
Publicado: (2022)

Eosinophil as a biomarker for diagnosis, prediction, and prognosis evaluation of severe checkpoint inhibitor pneumonitis
por: Li, Yanlin, et al.
Publicado: (2022)

Extracranial abscopal effect induced by combining immunotherapy with brain radiotherapy in a patient with lung adenocarcinoma: A case report and literature review
por: Lin, Xinqing, et al.
Publicado: (2019)

Comprehensive characterization reveals sputum supernatant as a valuable alternative liquid biopsy for genome profiling in advanced non-small cell lung cancer
por: Xie, Xiaohong, et al.
Publicado: (2022)

Tumor immune microenvironment and mutational analysis of tracheal adenoid cystic carcinoma
por: Wang, Fei, et al.
Publicado: (2020)

Predictive factors and prognosis of immune checkpoint inhibitor-related pneumonitis in non-small cell lung cancer patients
por: Liu, Xiaoyu, et al.
Publicado: (2023)

Effects of combining immune checkpoint inhibitors and anti-angiogenic agents on bone metastasis in non-small cell lung cancer patients
por: Xie, Xiaohong, et al.
Publicado: (2023)

Unexpected favorable outcome to etoposide and cisplatin in a small cell lung cancer transformed patient: a case report
por: Xie, Zhanhong, et al.
Publicado: (2019)

The clinical analysis of pulmonary lymphoepithelioma-like carcinoma with epithelioid granuloma
por: Gao, Guoying, et al.
Publicado: (2020)

Identification of the Unique Clinical and Genetic Features of Chinese Lung Cancer Patients With EGFR Germline Mutations in a Large-Scale Retrospective Study
por: Lin, Xinqing, et al.
Publicado: (2021)

Successful therapy with bevacizumab combined with corticosteroids for crizotinib-induced interstitial lung disease
por: Xie, Xiaohong, et al.
Publicado: (2019)

Pneumonitis Induced by Immune Checkpoint Inhibitors: From Clinical Data to Translational Investigation
por: Zhu, Shicong, et al.
Publicado: (2020)

Incidence and outcome of immune checkpoint-induced pneumonitis in oncology patients with history of pulmonary disease
por: Allen, Emily, et al.
Publicado: (2023)

Treatment response and safety of immunotherapy for advanced non-small cell lung cancer with comorbid chronic obstructive pulmonary disease: a retrospective cohort study
por: Zhang, Kening, et al.
Publicado: (2022)

Immune checkpoint inhibitor-related pneumonitis in non-small cell lung cancer: A review
por: Hao, Yuxuan, et al.
Publicado: (2022)

Dosiomics and radiomics to predict pneumonitis after thoracic stereotactic body radiotherapy and immune checkpoint inhibition
por: Kraus, Kim Melanie, et al.
Publicado: (2023)

Case Report: Nintedanib for Pembrolizumab-Related Pneumonitis in a Patient With Non-Small Cell Lung Cancer
por: Xie, Xiao-Hong, et al.
Publicado: (2021)

An oxidative stress biomarkers predict prognosis in gastric cancer patients receiving immune checkpoint inhibitor
por: Deng, Guiming, et al.
Publicado: (2023)

Differentiation of COVID-19 Pneumonitis and ICI Induced Pneumonitis
por: Dumoulin, Daphne W., et al.
Publicado: (2020)

Risk of Pneumonitis Associated With Immune Checkpoint Inhibitors in Melanoma: A Systematic Review and Network Meta-Analysis
por: Sun, You-Meng, et al.
Publicado: (2021)

Radiation Recall Pneumonitis After Treatment With Checkpoint Blockade Immunotherapy: A Case Series and Review of Literature
por: Riviere, Paul, et al.
Publicado: (2021)

A first case report of clinical response to targeted therapy in a patient with primary myoepithelial carcinoma of the lung harboring EGFR exon 19 deletion
por: Xie, Xiaohong, et al.
Publicado: (2020)

Trastuzumab-Induced Interstitial Pneumonitis
por: Errisuriz, Kimberly, et al.
Publicado: (2023)

CXCL9 Is a Potential Biomarker of Immune Infiltration Associated With Favorable Prognosis in ER-Negative Breast Cancer
por: Liang, Yuan-ke, et al.
Publicado: (2021)

Chinese expert consensus on the multidisciplinary management of pneumonitis associated with immune checkpoint inhibitor
por: Wang, Wenxian, et al.
Publicado: (2022)

Risk of Developing Checkpoint Immune Pneumonitis and Its Effect on Overall Survival in Non-small Cell Lung Cancer Patients Previously Treated With Radiotherapy
por: Barrón, Feliciano, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_rjvns5okuak4rnbhhft1g3n0o3